Recent Trends in the Development and Manufacturing of Fusion Proteins as Therapeutics
This webinar discusses the development and manufacturing of fusion proteins. Fusion genes are created by joining two or more genes each coding for separate proteins. Recombinant “antibody fusion proteins” are created artificially by recombinant DNA technology by fusing the constant region (Fc) of an antibody with another biologically active protein such as a cytokine, enzyme, or toxin. These fusion proteins combine the targeting ability of the non-antibody partner with the long serum half-live and stability of a monoclonal antibody. Trends and challenges in producing fusion proteins are discussed including a case study describing the development and cGMP manufacturing of a fusion protein.